Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Sponsor Directory

Pfizer clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
3277
Shown on this page
12
Current sort
Recently updated
Sponsor scope
Pfizer
Additional filters apply within this sponsor.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this sponsor

These controls apply only within Pfizer. Default order is Recently updated. Add condition, therapy, location, or recruitment status to narrow this sponsor page further.

Reset sponsor filters
Clear filters
Showing 289–300 of 3,277 matching trials for sponsor Pfizer.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

NCT06333899
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma, Glioblastoma, Glioblastoma Multiforme, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Midline Glioma, H3K27-altered
Interventions
Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2, Lorlatinib post Radiation
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 21 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2035
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 28, 2026, 11:05 PM EDT
Completed No phase listed Observational

A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.

NCT07261085
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir-ritonavir, No treatment
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
99,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 28, 2026, 11:05 PM EDT
Not yet recruiting Phase 2 Interventional

Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva

NCT07672782
View directory record Official record
Conditions
Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva
Interventions
Tisotumab Vedotin
Drug
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 28, 2026, 11:05 PM EDT
Active, not recruiting Phase 2 Interventional

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

NCT05323955
View directory record Official record
Conditions
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
Interventions
Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab, Tucatinib
Drug
Lead sponsor
Carey Anders, M.D.
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 28, 2026, 11:05 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

NCT02764541
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Tamoxifen, Palbociclib, Endocrine Therapy
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2031
U.S. locations
11
States / cities
Stamford, Connecticut • Brewer, Maine • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 28, 2026, 11:05 PM EDT
Not yet recruiting Phase 2 Interventional

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

NCT07247097
View directory record Official record
Conditions
Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
Interventions
Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide, Bortezomib for Injection, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 28, 2026, 11:05 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Adults

NCT07086677
View directory record Official record
Conditions
Streptococcus Pneumoniae
Interventions
PG4 vaccine in Buffer 1 with low dose PA-001, PG4 in Buffer 1 with low dose PA-002, PG4 in Buffer 1 with high dose PA-001, PG4 vaccine in Buffer 1 with high dose PA-002, PG4 vaccine in Buffer 2, 20-valent pneumococcal conjugate vaccine, Saline injection
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 84 Years
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
20
States / cities
Lake Forest, California • Rolling Hills Estates, California • Greenacres City, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 28, 2026, 11:05 PM EDT
Recruiting Phase 2 Interventional

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

NCT05071937
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
ZEN003694, Talazoparib
Drug
Lead sponsor
Alexander B Olawaiye, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 28, 2026, 11:05 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

NCT06106308
View directory record Official record
Conditions
Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Interventions
Onvansertib, FOLFIRI, Bevacizumab, FOLFOX
Drug
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 28, 2026, 11:05 PM EDT
Recruiting Phase 2 Interventional

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

NCT07454382
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab-bcmm, Cyclophosphamide
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 28, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

NCT04255875
View directory record Official record
Conditions
Healthy, Sickle Cell Anemia
Interventions
Placebo, PF-07209326
Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
16
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 28, 2026, 11:05 PM EDT
Active, not recruiting Phase 3 Interventional Results available

PALbociclib CoLlaborative Adjuvant Study

NCT02513394
View directory record Official record
Conditions
Breast Cancer
Interventions
Palbociclib, Standard Adjuvant Endocrine Therapy
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
5,796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
192
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 138 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 28, 2026, 11:05 PM EDT

About this Pfizer sponsor directory page

What this page lists
U.S. ClinicalTrials.gov public records where Pfizer is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pfizer trials.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, or open the full search for Pfizer.